Circulating tumor cells (CTCs) have become a blistering topic of discussion for oncologists because of their tremendous potential in the diagnosis and treatment of cancer. Over the past few years, they have been doled with quite an amount of research in this area understanding that CTCs are shed from tumors and circulate in the bloodstream. This process can also occur at an early stage of cancer. The major limitation in isolation of CTCs is their availability in limited numbers. Hence, many techniques have been developed and are under continuous improvement to enhance their effi cacy of CTC isolation and enumeration. They have shown their potentiality to not just indicate the presence of a tumor but also to provide us with its core information. They have also proven to be useful in detecting minor subgroups of cells present in the primary tissue which might eventually be the cause of treatment resistance or relapse of the disease. Hence, detecting and characterizing CTCs can defi nitely become an inevitable step in treating solid tumor malignancies. In this review, we have tried to comprehend the basics of CTCs including isolation, detection, characterization, and molecular mechanism of their circulation in the blood stream. We have mostly focused on the signifi cance of CTCs in diagnosis and therapies of four most common types of cancers, namely, breast, prostate, lung, and colorectal. This review provides the coverage of most of the advancements with regards to different tumor malignancies and their probable use in predicting outcomes of the disease to realize the concept of personalized medicine.
Introduction
Cancer is a collective term for uncontrolled malignant tumor growth taking place in any tissue of the body. More than 100 types of cancers are known till date, some of them being more common in specifi c genders such as in case of women; breast cancer is of the most common whereas in men, prostate cancer is quite common. [1] Other types of cancer like lung, colon, blood, lymph are found in both men and women. Surgery, radiotherapy, chemotherapy are the established treatments for cancer which also constitute signifi cant side effects. However, there is still a long way to go to constitute 100% effi cacious results because of heterogeneity and resistant of tumor cells to available therapies of cancer. [2] Each of the subtypes responds differently to the treatment and makes it diffi cult to attain a replete cytogenic response. Cancers are also known for attaining complex diversity which makes it diffi cult for clinicians to choose the treatment procedure. [3] Some prevalent mutations or the ones attained during the course of treatment may also result resistance to the therapy. In such cases, continuation of the same treatment only worsens the condition, therefore, there is a need of extremely specifi c and targeted therapy which can help the survival of patients in such situations. [4] It is increasingly becoming a prerequisite to take a "fi ngerprint" of a given tumor and then proceed with a "tailor-made" treatment. Circulating tumor cells (CTCs) can provide us with the required information and pave a new avenue in future cancer therapies.
Mechanism of Cancer Development
Most cancer remains asymptomatic at early stages and start showing up signs only in later stages of development. It is diffi cult to treat the patient in advanced stages of cancer, because the tumor spreads itself in various tissues of the body which is referred as invasion and metastasis of cancer. [5] The actual trigger which initiates this process remains obscure. However, CTC-based technologies may predict the pathway of metastasis. A malignant tumor cell has many cell cycle pathways abnormally regulated. Initially, the epithelial cells of a primary tumor infest nearby blood or lymphatic vessels and circulate in them as shown in Figure 1 . Of the many altered pathways in these cells, one of them is the production of a protein called matrix metalloproteinase (MMP). [6] Upon metastasis of a tumor cell, it breaks from the main tumor and enters the extracellular space which is mainly made up of collagenous fi bers. The tumor cells secrete MMP, which breaks collagen fi bers as well as the basement membrane surrounding the blood and lymph vessels.
The tumor cells now gain direct access to the epithelial membrane of the vessels and squeeze into them through the tight junctions. [7] Once into the bloodstream, they can easily transport to other tissues of the body and invade them. An aggressive tumor cell can attach itself to the endothelial membrane of the vessel and create a "pore" through which it escapes out and invade the nearby tissue. [8] Other less aggressive tumor cells can use this pore to enter the same tissue and establish a new tumor. Malignant tumors also initiate angiogenesis to enhance blood supply around the tumor and support its growth and development. [9] All this time, when several changes are taking place during the course of tumor growth, an important phenomenon is the shedding of cells from the primary tumor in the bloodstream as CTCs. [10] These cells carry tremendous information about the presence of tumor, its growth stage and mutations that it harbors. Due to this vital data, they have enormous applications in the detection, staging and treatment guidance of solid tumor malignancies. In this review, we have discussed about their signifi cance, isolation, enrichment techniques and the advancements in the fi eld of molecular biology of CTCs in major types of cancers including breast, prostate, colorectal, and lung cancer.
Circulating Tumor Cells
CTCs are described as cells shed by a primary tumor into vasculature and they keep circulating in the blood stream of cancer patients. [10] Scientists have tried to decipher their nature and signifi cance. CTCs are known to be circulating in the body fl uids before they metastasize to various parts of the body even in primary stages of the disease. [10] However, they are not easily identifi ed, as they are present in a very small numbers. It is estimated that a teaspoon of blood might contain just about 5-50 CTCs. CTCs fi rst exuviate from the primary tumor and remain in the blood stream for a while till the time it wedges itself in a new tissue as shown in Figure 1 . Some CTCs can adhere to the wall of capillaries and bunk to enter a new tissue. While in the blood stream, they might even clog capillaries due to their big size. [11] Many CTCs can be shed from a given tumor in different locations. A given tumor may vary in nature at different locations, that is, it may display heterogeneity. CTCs released from different locations of a tumor may exhibit discrepancies of a given tumor. Thus, CTCs can contribute to a potpourri of heterogeneous cells disgorged from the same tumor. [11] Despite consistent efforts, researchers are yet to gather its caboodle. Of the known properties, one of them is that they undergo epithelial to mesenchymal transition (EMT) as shown in Figure 2 . This results in change with respect to epithelial markers and other cellular properties. [12] An epithelial cell starts behaving like a mesenchymal cell and can detach itself from the parent tissue and become a free fl owing entity. CTCs use this property to invade blood and lymph capillaries and swim freely in them. Not all CTCs undergo complete EMT; some of them undergo just partial changes or partial EMT. CTCs undergone complete EMT can revert their phenotype by undergoing mesenchymal to epithelial transition (MET) out of which some can contribute to micro or macro-metastasis leading to cancer progression. [13] When a tumor cell undergoes reversion by MET, they regain properties of cell adhesion. These cells fi rst adhere to the wall of capillaries and then evade from them to nearby tissues. Since they can now behave as epithelial cells again; they adhere to the target site and start dividing and re-dividing giving rise to a new tumor. However, EMT transition can also lead to a perplexed situation as there is a lot of diversity in the morphological transformations.
Signifi cance of CTCs
One of the most axiomatic implications of CTCs is that they are minimally invasive indicators. [12, 13] Detection of CTCs can reveal mint of information rather than just the presence of a tumor. They can help us to realize the concept of tailor-made medicine. Analysis of CTCs can save a patient from worsening the condition with unsuitable medications. Furthermore, the earlier they are detected, faster and better treatment options can be made available to the patient. It provides the basis of understanding mutations and genotypic changes of malignant cells and hence provides the best suitable targeted therapy. CTCs are multifunctional biomarkers and enable us to assess the patient serially along the treatment journey. They are potentially an alternative to invasive biopsies for detection, characterization and monitoring of non-hematological cancers. [14] Although as of now it is not clear whether CTCs are the cause of metastasis, they still hold the potential for being a cause for disease progression. Metastasis is better known to be caused by cancer stem cells (CSCs), which are highly motile, self-renewing cancer initiators. They also have increased resistance to apoptosis as well as to certain treatment drugs. CTCs with such properties can be metastatic in nature. CTCs after undergoing EMT can also make non-CSC type cells to behave like CSCs. In addition, it is yet to be clarifi ed whether cells with metastatic potential have increased motility and aggressive nature of CTCs as compared to non-metastatic tumor cells. On the whole, CTCs give us biological insights of the disease condition, progression, and treatment prediction. Reports indicate that patients with fewer numbers of CTCs survive longer than the patients which have more number of CTCs. [15] Another important implication of CTCs is that they can form the constitutional basis of tumor staging. [16] The types and quantity of CTCs can form prima facie of the degree and type of cancer. They can be periodically used to keep a check on disease progression. In some cases, they have even been able to identify the drug targets by analyzing the enumerated CTCs and its phenotype. They can even help in the selection of secondary treatment options while the patient has failed to respond to fi rst line treatments. [17] One such example is the detection of human epidermal growth factor receptor 2 (HER2)-positive CTCs in HER2-negative breast cancers. [18] Thus, it gives us hints and specks about quiescent population that may be present in the tumor and be the cause of drug resistance or relapse of the disease. [19] Since, CTCs hold such critical information about a tumor and its characteristics; they can defi nitely form the pedestal of patient-specifi c treatments. The great enigma about cancer can adjudicate with the help of information retrieved from CTCs analysis.
Isolation and Analysis of CTCs
In the recent years, CTCs have gained increasing importance because of their multi potential uses. Despite their long known discovery and spates in clinical oncology, no method has been devised to isolate or enumerate CTCs effi ciently. Primarily, their quantity in blood circulation is the biggest hurdle in isolation of CTCs. Out of the several CTCs shed by the primary tumor only about 0.1% survives in the circulation and only about 0.01% is responsible for metastasis. [17] It has been reported that CTCs are not continuously shed in the circulation. They are discontinuous and might not be present in homogenous condition. Thus, while isolating CTCs a single blood sample might fall insuffi cient or may give inaccurate results. [20] This is accompanied by further reduction in their numbers when they get clogged in capillaries due to their large size. They can also form clusters while fl owing and some of them may even adhere to the walls of the capillaries, or some might be cloaked by the platelets. Further reduction in CTCs number takes place during batch processes which are followed for their enrichment. Simpler methods involve size based separation, collagen adhesion method or density-based separation. Other sophisticated ones rely on epithelial markers, immunomagnetic techniques, microchips, and nanotech approaches. [21] Density-based Ficoll-Hypaque method
Gertler et al. [22] 2003 have used Ficoll-Hypaque density-based separation method to separate tumor cells from bone marrow and peripheral blood aspirations. It is based on differential migration of cells which takes places during centrifugation and gives a layered separation of cells types. The porous barrier is permeable to the red blood cells and other smaller components of blood. The buffy coat above this layer is of concern, as it contains the tumor cells along with leukocytes. This layer can be easily aspirated and analyzed further to determine the presence and quantifi cation of CTCs. [21] 
Immunomagnetic (antibody based) method
This method exploits the presence of surface markers on tumor cells or hematopoietic cells. In this method, antibodies are coupled with magnetic particles and then used for positive or negative selection of CTCs. In positive selection, surface markers of CTCs are targeted, whereas, in negative selection, depletion of blood cells other than CTCs is achieved by targeting their surface markers [23] as shown in Figure 3 . Epithelial cell adhesion molecule (EpCAM) is one of the most widely tapped markers on tumor cells. CD45 in case of lymphocytes and glycophorin for erythrocytes are two commonly used markers in case of negative selection. MACS ® has introduced microbeads which can be used in such negative selection. [24] Food and Drug Administration (FDA) has approved CellSearch ® (by Janssen Diagnostics) which is by far the most effi cacious system for extraction and enumeration of CTCs. [25] The CTCs according to this system are defi ned by a characteristic round oval shape cells with nucleus which is stained by 4',6-diamidino-2-phenylindole stain. This procedure may be laborious and intensive but gives the best enrichment results as a comparison to other existing techniques. It makes use of antibodies like EpCAM attached to magnetic beads for binding to specifi c tumor cell surface receptors. These cells can be pulled out from the rest of cells under the infl uence of a magnetic fi eld. [26] Some tumor cells might escape the antibodies as they undergo EMT transitions while some other tumor cells belonging to a smaller sub-population might also be ignored. Some CTCs remain undetected throughout this process. [27] Hence, although this method is being used currently for experimental purposes, there is yet lot of scope for improvisation in the quantitative as well as qualitative aspects of tumor cell detection.
Microfl uidics method
As antibody-dependent cell sorting is not a completely reliable source. There are a lot of hurdles in accomplishing higher percent enrichment of cells from the whole blood. Hence, it is important to take into consideration other methods which rely on antibody-free systems. In this method, cell size-based sorting is accomplished using microfl uidic technology. [28] The microfl uidic chamber is made up of special materials and is usually spiral or curvilinear. When whole blood is allowed to pass through this micro-chamber, inertial lift forces and drag forces help in sorting of the cells. These forces rely on differential sizes of cell in the sample. In case of CTCs, whole blood or leukocyte along with CTCs fraction can be used as a feed in input. As they pass through the microfl uidic chamber, the forces will act on the cells and start separating them based on size. The CTCs incline more towards the inner wall (larger size) while other cells such as white blood cells and red blood cells will incline towards the outer side of the wall (smaller size). [29] They can be collected in separate fragments at the end of the tube, where it bifurcates into collecting chambers as shown in Figure 4 . Recent advances have allowed the procedure to be carried out with minimal loss of cell types. [30, 31] 
Size based separation method
As CTCs are usually bigger in size compared to other components, this characteristic is put to use. This method can even be used to detect the presence of a single tumor cell in a quantity of blood as little as 1 mL (shown in Figure 5 ). ISET ® is one such established method which is used for such type of cell size based sorting. Specially designed fi lter are employed to allow blood components to percolate through them. CTCs being bigger in size will not be able to pass through the membrane and hence remain over it. They can be then collected from over the membrane fi lter and subjected to analysis. [32] Other techniques
The FDA approved cell detection method has quite some limitations. Hence, a lot of attempts are being made to invent better techniques which are highly effi cient low on cost, less labor intensive, and time savers too. Metacell ® is another cell size-based sorting method which has been introduced lately. [32, 33] Microchips and micro slides are being designed to exploit various differential properties of cells. Lu et al. [34] have introduced a device which they refer to as Nan Velcro CTCs Chip. They claim that this device is much more effi cient and reproducible as compared to CellSearch ® kit. This kit is composed of a patterned silicon nanowire substrate which is overlaid with polydimethylsiloxane mixture. [34] While another cell surface marker-based systems is a fl ow cytometry fl uorescenceactivated cell sorting. [35] Another emerging technique is making use of dielectric constants of cells such as the DEPArray system. [26] Ju et al. [36] have described a method where they make use telomerase activity to isolate melanoma cells in peripheral blood. As telomerase activity is elevated in cancerous cells rather than normal cells, they made use of an adenoviral vector human telomerase reverse transcriptase to drive the expression of green fl uorescent protein which can be used to isolate CTCs in this method. An interesting device called VeriFAST is an integrated system which can isolate cells as well as perform down streaming processes including staining with EpCAM and other antibodies to isolate CTCs. [37] Many more such technological advancements have been reported by scientists all over the world. There are several newer assays are being introduced which are focused on marker free isolation such as chromatography, fi ltration, and dielectrophoresis for capturing CTCs from cancer patients. [38] Few of them have been mentioned under specifi c cancer categories discussed ahead in this review. 
Characterization and Molecular Profi ling of CTCs
We have discussed various CTCs enrichment techniques which are being used for isolation of CTCs from metastatic cancer patients. However, none of them has achieved much of quantitative success. The results have shown a great amount of variation from 10% to 90% of isolated CTCs and hence, it is crucial to analyze the collected cells for their quantity as well as their exact phenotype. A numerical indication of collected CTCs may not be able to reveal the true picture of the type of cells isolated from cancer patients. Similarly, tumor cells can undergo a variety of changes and be present in heterogeneous subpopulations. Hence, a mere number of CTCs can lead to faulty conclusions. Therefore, there is a need for true characterization of these isolated CTCs cells to come to logical conclusions. Molecular profi ling of these isolated cells will crystallize the picture, as it reveals the true nature of the isolated CTCs cells.
A fundamental process in EMT, down-regulates E-cadherin, which can be attained by many transcriptional factors. [39] Most of the molecular markers that have been isolated for characterizing CTCs are EMT indicators. During EMT process, a metastatic cell goes through a lot of modifi cations at cellular and molecular levels and many genes undergo transcriptional alterations.
[39] Some of these genes play a role in initiating the effect of EMT while others play a role in regulating and maintaining its transited state. The other factors like infl ammatory cytokines and physical changes in the tumor microenvironment also play a role in EMT promotion. [39] TWIST1 and TWIST2 genes are most strongly expressed genes in EMT process which are responsible for inducing transformation alone or in co-operation with other factors such as TGFβ, Wnt, Notch, etc. [40] E-cadherin is one of the most important proteins for maintaining the epithelial nature of cells. Snail1 and Snail2 suppress the transcription of E-cadherin as well as Zeb1 and Zeb2 genes. This results into downregulation of E-cadherin, which leads to initiation of EMT process. [41, 42] Other gate keeper's genes of epithelial state, such as alpha and gamma catenins are also been down-regulated along with downregulation of E-cadherin in this process. [43, 44] Induction of certain mesenchymal characters during EMT process requires upregulation of two extracellular matrix proteins, that is, vimentin and fi bronectin in these cells which escape the barriers of local tissue and proceeded for invasion. Similarly, other genes such as N-cadherin, CD44, intergrin β6 are also implicated for proper migration of these cells. [43] [44] [45] [46] Even understanding the mutational changes, abnormal size, and characteristics of CTCs, scientists are still pondering over the fact that these cells are able to survive in an environment which is totally hostile for them. It is postulated that out of the several hundred CTCs shed by the tumor, only a few remain in the circulation. There are reports suggesting that CTCs bearing mutations, such as upregulation of CD47, help them in escaping attack by natural killer cells and macrophages. Similarly, downregulation of chaperone protein-calreticulin again helps them to dodge the immune system. [47, 48] Schölch et al. [49] in their studies have referred this state as an "immune-evasive" to the period between EMT and MET in circulation. Thus, overall it seems that CTCs have very evolved mechanisms to maintain and express their invasive aggressive nature by surpassing the body's natural immune system.
CTCs in Breast Cancer Diagnosis and Treatment
Breast cancer is one of the most common types of cancer detected in women. Last two decades, due to early diagnosis and advancement in treatment protocols, breast cancer mortality has been considerably reduced. However, there is no hope of survival when patient condition progresses to the metastatic stage. Recent studies have shown that CTCs which are shed from tumor are mediator of metastatic dissemination and form micrometastasis at distant organs. [50] Due to advancement in technology, several methods have been established to isolate CTCs from metastatic breast cancer patients. CTCs derived from breast cancer patients are among the most extensively studied for diagnosis and treatment of breast cancer. [50] There is a direct co-relation of CTCs with disease prognosis and survival has been reported in many cases. It has been shown that if there is more number of CTCs, there are less chances of survival. [50] The progression of the disease and its response to treatment can be very well-monitored by characterizing CTCs which are disseminated from the primary tumor. It has shown that the presence of CTCs, despite of ongoing treatment, is an indicative of worse overall survival. [51] Hence, it is very important to characterize CTCs for better understanding of this disease progression and cure. [51] Due to large size and few numbers of CTCs in blood circulation of metastatic breast cancer patients, the isolation and enumeration of captured CTCs have proven to be of prognostic value in breast cancer evaluation and treatment. One of technologies presently in use is the CellSearch ® system, which works on a principle of selecting CTCs as per the positive expression for EpCAM and cytokeratin (CK) protein on the surface of these cells. [52] Although it has proven greatly useful and reproductive, it may limit the selection due to EMT transition process. CTCs which have undergone EMT will show downregulation of epithelial markers including EpCAM. [52] In some cases, it has been observed that HER2-positive metastatic breast cancer shows the presence of EpCAM negative CTCs. [53] Hence, EpCAM independent methods could fetch an increase in number of capture of CTCs. Second, detecting CTCs on the basis of HER2 expression has been suggested in many cases. CTCs vary in expression and frequency of this gene, and it can be directly correlated with the disease's progression and survival. [54] Not only about correlating the primary tumor's characteristics, CTCs can reveal more vital information, which is at times not detected by mere analysis of primary tumor. In a particular group of HER2-breast cancer patients, HER2+ CTCs are identifi ed. [55] This leads to consideration of revision in the ongoing treatment of the disease. Trastuzumab-based therapy is applied to these patients with HER2+ CTCs and HER2-primary tumor. This study has shown that 1 out of 4 patients are treated completely while 2 patients have attained partial response to this treatment. Even though this study number of patients are few, it has given important facts about CTCs. It has helped in identifying the changing course of the disease well before time. Thus, CTCs hold the potential to represent the metastatic state of HER2-breast cancer. [55] CTCs have been reported to harbor many types of mutations and transformations. Obermayr et al. [56] have shown that genes like EpCAM and secretoglobin, family 2A and SCGB2A2, can be used as important markers in the detection of CTCs in breast cancer. CTCs have been reported to establish mutations after dissemination from the primary tumor and some of these mutations may help the circulating cells to attain enhanced survival and therefore molecular profi ling of CTCs holds the importance in understanding the real state of disease. Monitoring the CTCs with respect to CK19 expression can reveal the nature of metastatic potential of the tumor. CK19 expression in CTCs has been prognostic for worse overall outcome of the disease. CK19 as well as TP53 mutations are mostly found in all of the CTCs derived from triple negative breast cancer patients. [57] Some researchers believe that it can be one of the driving factors to the progression of the disease to triple negative stage. [53] It has also been shown that breast cancer patients which expressed KRT19, SCGB2A2, and ERBB2 genes showed poor survival rates. [56] IGF-IR mutation has also been observed to be expressed in patients of breast cancer at a metastatic stage of disease. Furthermore, mutations in PIK3CA gene and ERBB2 mutations are reported in CTCs of some patients whose primary tumor did not share this state of disease. [57, 58] Apart from these mutations, EMT changes have been one of the critical properties of CTCs. Most of the CTCs isolated from breast cancer patients show the presence of EMT markers such as ETV5, NOTCH1, SNAIL, TGFB1, ZEB1, and ZEB2. [41] The mutational and transitional changes taking place in CTCs make them gain an aggressive behavior which in turn helps them to break apart from the basement membrane and disseminate from the tumor. [59] EMT pathway and PIK3CA mutations have been related to progression of the disease to metastasis in many cases. [60, 61] Hence, molecular profi ling of CTCs is becoming increasingly important both to understand the state of the disease and then select an optimal treatment for a given patient. [62] It has been reported that the presence of genes like EpCAM, CCNE2, DKFZp762E1312, EMP2, MAL2, PPIC, or SLC6A8 can be related with the presence of CTCs in peripheral blood. [56, 62] In breast cancer, chemotherapy is one of the standard modes of treatment. During the course of this therapy, CTCs values are determined before and after rounds of chemotherapy. In most of the cases with non-metastatic state of breast cancer, reduction in number of CTCs is observed after the fi rst round of chemotherapy. However, it was also noted that CTCs had a tendency to attain resistance to the therapy. Hence, it is suggested that a regimen of increasing doses should be deployed in the progressing rounds of chemotherapy. [63] Studies by Peeters et al. [64] have revealed some statistics about CTCs count and disease state. In a small group under their study, about 80% of patients who had more than 80 CTCs in 7.5 mL of blood died within one year from diagnosis of metastasis of disease. In a similar study by Smerage et al., [65] it has been observed that CTCs continued to remain detected after fi rst round of chemotherapy in some patients of breast cancer. It is observed that such patients are in rapid progression of the disease to metastasis. They have further suggested that in such cases, it can be ideal to opt for some alternative treatment with some of the novel therapeutic agents rather than continuing with the same chemotherapy. [66] 
CTCs in Prostate Cancer Diagnosis and Treatment
Prostate cancer originates in the prostate gland of male reproductive system. Fusion of TMPRSS2 and ERG genes is identifi ed as one of prime reasons leading to prostate cancer which is often accompanied by loss of PTEN. [67] Biopsy remains the test for full confi rmation of this disease. Less invasive processes are sometimes conducted to detect this disease as well as to understand its progression. Prostate-specifi c antigen (PSA) level detection is one of such tests which can be used to identify the presence of disease and monitor the treatment effect in these patients. However, PSA levels may not be always necessarily indicative of the disease progression as PSA level may raise due to reasons other than prostate cancer. Similarly, fall in levels of PSA during treatment may not be necessarily indicative for the eradication of the prostate tumor. It has been shown that drugs targeting androgen receptor (AR) may bring down levels of PSA but not necessarily cure the disease simultaneously. Hence, a better prognostic marker is greatly demanded. When PSA testing falls insuffi cient to validate the course of treatment, CTCs isolation enumeration and characterization can act as a reliable marker for diagnosis and therapy of prostate cancer. [68, 69] In a study by Attard et al. [70] have captured circulating, non-apoptotic nucleated, EpCAM+ CK+ CD45-cells from prostate cancer patient's blood and confi rmed for their malignant origin and hormone-regulated expression of ERG1. Thus, CTCs hold great potential to identify and stage the prostate cancer with minimal invasive procedures. [70] Giesing et al. [71] have identifi ed overexpression of fi ve genes, namely, SOD2, GPX1, AR, cyclin B, and bFGF which have predicted the clinical stage of metastasis and 3 of these genes are related to bone metastasis. [72] CTCs are known for their heterogeneity acquired due to frequent transitions from epithelial to mesenchymal state. Some of these EMT mutations are more frequent in castration-resistant prostate cancer than compared to hormone-sensitive prostate cancer. They can be used to identify specifi c targets in variants of the same type of cancer. These mutations can be used as a checkpoint and also help to speed up this testing as well as validation of upcoming therapies. In prostate cancer, CTCs have been proposed to act as intermediate or surrogate endpoints for survival and to shorten timelines for drug approval. [73, 74] Changes in levels of CTCs can be correlated with the disease status. Patients with lower levels of CTCs have shown slower disease progression in comparison to those having a higher amount of CTCs. [75] CTCs are sure to provide a better overall picture of the state of disease as there are molecular variations in different sites of metastasis. Shaffer et al. [76] demonstrate an example of variation in EGFR ranging from 0% to 100%. Hence, understanding the heterogeneity in the disease cannot be understood from the single site biopsy and profi ling of these CTCs becomes a necessity. Leversha et al. [77] have shown that molecular characterization of CTCs may be possible for reporting genomic amplifi cation of AR and chromosomal instability in prostate cancer patients. There is very much high expression of MYC and TMPRSS-ETV genes and downregulation of PTEN. [77] Such copy number alterations have been related to aggressive tumors. [78] CTCs exome sequencing has proven its clinical signifi cance. Major percentage of cancer mutations are detected in CTCs, which matched the primary tumor. Furthermore, a great percentage of mutations could be predicted and matched with the metastatic site of tumor. The presence of more than 5 CTCs in 7.5 mL of blood has been related to poor outcome of the disease treatment in metastasis. [75] Hence, not only is it benefi cial in providing prognostic information, but it can also act as a gateway to treat those patients in a better manner whose tumors do not shed CTCs. [79] Newer technologies continue to emerge with the growing research. Lu et al. [34] have introduced NanoVelcro CTCs chip which claims to have better and reproducible results as compared to FDA approved CellSearch ® kit. Olmos et al. [80] have made use of reverse transcription polymerase chain reaction (PCR) to identify telomerase activity in CTCs for which they are very sensitive. However, individual CTCs can be identifi ed with this method. Galletti et al. [81] made use of prostate cancer-specifi c antibodies i.e. prostate-specifi c membrane antigen, PSA, prostate specifi c stem cell antigen and EpCAM to evaluate isolation of CTCs in the metastatic stage of disease which might escape EpCAM specifi c selection. They have indicated isolation of specifi c CTCs including the one which undergoes EMT and escape EpCAM selection and organ-specifi c CTCs in the metastatic stage of prostate cancer. [81] 
CTCs in Colorectal Cancer Diagnosis and Treatment
Colorectal cancer (CRC) is one of the most dreaded diseases and has its poor prognosis. Although survival rates have drastically improved over time, timely prognosis would aid the treatment to a great extent using CTCs testing. The data available for earlier stages are yet bare and lacks good sample size for studies on CRC. Romiti et al. [82] have analyzed the prognostic role of CTCs, highlighting the importance of CTCs count before and after chemotherapy. However, to avoid misleading CTCs counts after surgery, it has been suggested that there should be a time gap of at least 24 h prior to post-surgical sampling. This is because the procedure may contribute to a temporary rise in CTCs which are rapidly cleared within 24 h. CTCs follow-up for patients with the aggressive disease can form an inevitable tool and also help in selecting better emphatic treatments. [82, 83] Barbazán et al. [84] have done molecular profi ling of CTCs derived from metastatic CRC. They have studied various molecular markers, such as VCL, ITGB5, BMP6 for invasive phenotype, TLN1, APP, CD9, LIMS1, and RSU1 for adhesion and migration for deeper understanding of the behavior of these prostate cancer cells. These markers can be used to profi le the type of tumor and to assist in selecting a suitable treatment. In some reports, researchers claim that a higher amount of CTCs is reported in mesenteric blood rather than peripheral blood. CTCs can be used to diagnose patients symptomatic for CRC in addition to fecal occult and lower gastrointestinal endoscopy. [85] Like other malignancies, dormancy of CTCs in CRC is another aspect to discuss because even after signifi cant exposure to treatment, some CTCs continue to be detected in the circulation. Molnar et al. [86] mention about detection of CTCs as individual cells or as clusters by a CK-based, immunomagnetic cell separation method. Although the number of CTCs decreases with the progressing treatment methods, at least a few of these cells or clusters are observed to be circulating in the blood stream for a long time despite operation. This could be explained by assuming that some CTCs remain dormant in condition for long durations and that they still continue to be present in the circulation.
Mutational analyses of CRC derived CTCs carried out by Bork et al. [87] have pointed out some clinically signifi cant characteristics. In particular, KRAS mutant CTCs are discovered in patients, whose primary tumor is KRAS wild type. An ultra-deep sequencing revealed the presence of KRAS mutated group of cells in the primary tumor. This is another example revealing the crucial importance of CTCs sequencing which helps us fi nd out details of the heterogeneity in the tumor which is otherwise not possible by single biopsy. CTCs have been directly related to state to disease and predicting treatment outcome in CRCs just like other cancers. Individual markers such as KRT19, MUC1, EpCAM, CEACAM5, and BIRC5 are studied by de Albuquerque et al. showing positively ranging between 15% and 35%. They have observed a shorter progression-free survival in patients showing more of these CTCs compared to the group of patients with lesser or no CTCs. [88] In an interesting study by Allen et al., [89] we come across the fi nding that CRC tumor-associated events such as apoptotic CTCs and CTCs debris are more indicative of liver metastasis in particular than just CTCs count. These events are more indicative of the site of metastasis rather than primary tumor and hence are clinically very signifi cant. [20] CRC has often been related to liver metastasis in particular. This is supported by detection of increased number of CTCs in mesenteries than peripheral blood. Though the prognostic value of these CTCs has not yet been validated. Denève et al. [90] in their studies strongly support that liver is the fi lter site for CTCs and that viable CRC disseminated cells can be isolated from hepatic tissue. Reports are pointing out that the EpCAM+ CTCs are often detected in liver indicating a strong signal of association of liver metastasis in CRC. In another study by Antolovic et al. [91] have noted worse overall survival in later stages of CRC patient-derived CTCs having CEA/CK/CD133 positive mRNA than those who are negative for these markers. They have discussed about use of additional markers like CD133 for detection of not only CK20+ and CEA+ subpopulation of CTCs but also for more aggressive type CD133+ disseminated cells.
Improvements in the detection of CTCs continue to evolve as the need does. In one study Antolovic et al. [91] have suggested the use of Ficoll gradient isolation prior to use of EpCAM enrichment technique of CTCs for enhanced results. In many cases, it is easier for clinicians to treat a suffering patient if the malignancy is detected earlier. Hence, in cases such as that of CRC where early detection still awaits some effi cient technique, CTCs can play a good enough role in not only detecting and personifying but also providing a real-time means of the disease status along the treatment journey.
CTCs in Lung Cancer Diagnosis and Treatment
Lung cancer is broadly classifi ed as small cell lung cancer (SCLC) and non-SCLC (NSCLC). Early detection continues to remain a challenge in lung cancer, reducing the chances of survival. Dissemination is an early event in both these types of lung cancer and hence CTCs can be of great use in lung cancer as the available biopsies are not readily procurable. [92] [93] [94] A study by Casavant et al. [93] provides signifi cant data of study on animal models demonstrating use of CTCs in SCLC as "liquid biopsy" and paving way for personalized medicine. The most common methods used for isolating CTCs in lung cancer are CellSearch ® and ISET kits. Both these methods indicate a higher number of isolation of CTCs in SCLC than NSCLC. Taenzer et al. [92] have explained this by the possibility of EMT in NSCLC, which makes the disseminated cells escape EpCAM selection. Mutations on exon 19 and 21 of EGFR are the prime target of drug-based therapies. Other mutations such as T790M, EML4-ALK rearrangement, BRAF, KRAS, HER2, PIK3CA/AKT1, ROS, FGFR1, and MET are also of greater interest in lung cancer as clinical trials are now focused on mutation based therapies. [95, 96] Molecular characterization of CTCs holds great importance as it can provide a very plausible means of mutation detection. Furthermore, one can be easily monitored periodically for the development of any resistant mutations during the course of treatment. [97] [98] [99] Higher number CTCs in lung cancer has been associated with larger tumor size and in particular in bone metastasis. [100] [101] [102] CTCs have surely gathered lot of enthusiasm and effort towards their research with their staggering clinical potentials. But till date research on them has been limited by many factors, such as their small capture number being a major problem. Kolostova et al. [35] have drawn an attractive protocol for isolation and culturing in vitro CTCs of human lung cancer. If CTCs can be cultured in vitro like other cells, it will be of great benefi cial value as it will pace up the investigation on the nature of CTCs and its characterization. Furthermore, circulating tumor micro-emboli (CTMs) have been reported in many cases of lung cancer. CTMs are cluster of disseminated tumor cells in circulation. CTM are of particular interest in this case as they are considered to be markers of extreme metastatic potential.
[103] Treatment response is a major question in advanced lung cancer. CTCs count can potentially help approve the ongoing treatment and also help in suggesting any alterations if required. [104, 105] Ilie et al. [105] in their discussion on CTCs in lung cancer have indicated possibilities of the presence of these cells even before angiogenesis. CTCs can be present in circulation long time before the disease can be actually detected. Therefore, they can become the core of research in regards of early detection of the disease for symptomatic patients. [106] [107] [108] 
CTCs in Other Cancers Diagnosis and Treatment
CTCs can be detected in almost all of the solid tumor malignancies and changes in the disease state can be predicted with the help of CTCs. Genes like VIM, TGFBR2, TGFB, and SERPINE1 which are indicative of mesenchymal phenotype, are expressed in higher levels in the CTCs of glioblastoma cancer in comparison to the cells of the primary tumor or cell culture. [109] [110] [111] TWIST and Vimentin are considered as diagnostic markers for hepatocellular carcinoma. TWIST is known to suppress expression of E-cadherin while overexpression of Vimentin is strongly related with the mesenchymal phenotype of these CTCs. Overexpression of ZEB1 and ZEB2 is also reported in this cancer. [112] So far, no specifi c marker has been reported for bladder cancer. However, it has been suggested that overexpression of H-RAS oncogene and mutations in FGR-R genes in CTCs could be considered as a diagnostic tool. [113] Apart from genes, other cellular transformations like loss of cellular junctions which aid in cell to cell communications are indicative of mesenchymal phenotype. Markers such as CK20, UP II, and EGFR have been related to diagnosis of bladder cancer. CTCs can be assessed to detect the presence of these markers and aid in the diagnosis of the malignancy. [114, 115] Alonso-Alconada et al. [41] have done molecular profi ling of CTCs isolated from metastatic endometrial carcinoma (EC) patients. They have shown that there is an overexpression of stem cell related genes, i.e. ALDH and CD44, EC related genes such as BRAF, PIK3CA, RELA, RUNX1, and EMT related genes, that is, ETV5, NOTCH1, SNAI1, TGFB1, ZEB1 in these patients. [41] Of these genes, ETV5, in particular, is strongly related to increased metastasis and CTCs plasticity. [41] Häfner et al. [116] have shown that the evaluation of level of HPV16-E6 mRNA by real-time PCR is more sensitive molecular marker expressed in CTCs isolated from metastatic cervical cancer patients than that of commonly used CK19 mRNA as a marker. Just like other solid tumors, in case of pancreatic cancer, several studies have similarly suggested the use of CTCs for not only diagnosing but also for identifying metastasis in patients and helping to select patient-specifi c therapies. [117] [118] [119] A study by Kuhlmann et al. [120] brings to light an importance of the molecular characterization of CTCs in ovarian cancer. They have shown that ERCC1+ CTCs can predict platinum resistance therapy in ovarian cancer which is still remains a big challenge in the treatment of ovarian malignancy. [120] Obermayer et al. [121] have shown that there are more number of cyclophilin C gene (PPIC) positive CTCs are detected usually in ovarian platinum-resistant cancer group as compared to the sensitive group than EpCAM positive CTCs in these patients. It is also related to poor outcomes of this disease. [121] Advancements in CTCs detection techniques have given rise to newer methods, such as the one-step detection of using fl uorescent silica nanoparticles for ovarian cancer. [122] With the growing technologies and persistent work on CTCs, we are slowly channelizing the efforts to derive a clearer picture of the use of CTCs in diagnosis and treatment of various cancers.
Future Directions
Taken together, CTCs have potential to aid in the entire course of a patient's cancer journey starting from diagnosis, treatment selection, post-treatment/surgery monitoring, and follow-up. Although vast amount of research have been accelerated in the fi eld of these disseminated tumor cells, their availability in scant numbers has limited research. We anticipate the development of isolation and enrichment combination techniques which help in avoiding cell loss. A range of specifi c markers is also bound to enhance the enrichment results as those cells which can escape EpCAM selection could also be captured. Given their tremendous potential to help change the enigmatic situation of solid tumors, we can conclude that CTCs are sure to become an inevitable part in the near future of solid tumors malignancies.
